Cho Soo Young, Choi Minhye, Ban Hyo-Jeong, Lee Chang Hyeon, Park Soojun, Kim HanKyeom, Kim Young-Sik, Lee Young Seek, Lee Ji-Yun
Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Research Institute for Veterinary Science BK21, Program for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea.
Department of Pathology, College of Medicine, Korea University, Seoul 02841, Republic of Korea.
Oncotarget. 2017 Jan 31;8(5):8095-8104. doi: 10.18632/oncotarget.14098.
Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.
宫颈小细胞神经内分泌肿瘤(CSCNETs)是罕见的侵袭性神经内分泌肿瘤(NETs)。目前缺乏可靠的CSCNET诊断和预后标志物,这使得诊断和预后预测困难,治疗策略也有限。在此,我们使用全外显子组测序(WES)提供了5对肿瘤-正常配对的CSCNETs的突变谱。我们扩大了对频繁突变基因的评估范围,纳入了来自55例小肠神经内分泌肿瘤、10例胰腺神经内分泌肿瘤、42例小细胞肺癌、6种NET细胞系和188例宫颈癌的公开可用数据,以及我们的5例CSCNETs。我们鉴定出1968个体细胞突变,包括1710个错义突变、106个无义突变、144个剪接位点突变、4个lncRNA突变、3个非终止突变和1个起始密码子突变。我们根据基因本体论为114个最频繁突变的基因赋予了功能。ATRX、ERBB4以及Akt/mTOR通路中的基因最常发生突变。在所有检测的CSCNET肿瘤中均检测到细胞质ERBB4免疫组化染色阳性,但在相邻正常组织中未检测到。据我们所知,本研究是首次利用WES对配对的CSCNET和正常组织进行检测以鉴定体细胞突变。进一步的研究将增进我们对ATRX和ERBB4突变以及AKT/mTOR信号传导如何促进CSCNET肿瘤发生的理解,并可能应用于新的抗癌治疗策略中。